Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
22 December 2022 - 12:30AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of therapeutics designed to activate the immune
response to cancers and infections, today announced the Company
will present expanded data on botensilimab in combination with
balstilimab at the American Society of Clinical Oncology –
Gastrointestinal Cancers Symposium (ASCO-GI), to be held January
19-21, 2023, in San Francisco, CA.
Expanded data from the microsatellite stable colorectal
(MSS-CRC) expansion cohort of the Phase 1 study of botensilimab (a
multifunctional Fc-enhanced anti-CTLA-4) in combination with
balstilimab (anti-PD-1) in cold (immunotherapy-resistant) tumors,
will be presented at a late-breaking oral session on January 21,
2023, at 10:00am ET.
Presentation Details:
Abstract Title: Results from a phase 1a/1b
study of botensilimab (BOT), a novel innate/adaptive immune
activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic
heavily pretreated microsatellite stable colorectal cancer (MSS
CRC) (NCT03860272)
Abstract Number: LBA8
Presenting Author: Anthony El-Khoueiry, MD,
Phase I Program Director at the USC Norris Comprehensive Cancer
Center, Keck Medicine of USC
Details: Saturday, January 21, 2023, at 10:00am
ET
Complete abstracts will be released on Tuesday, January 17,
2023, at 5:00pm ET. Data presented at the conference will be
available to view in the Publications section of the Agenus website
(https://agenusbio.com/publications) following the ASCO-GI
Meeting.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Forward Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to the use of botensilimab, for instance,
statements regarding therapeutic benefit and efficacy, mechanism of
action (including validation of mechanism of action), potency,
durability, and safety profile (including the absence of specific
toxicities) of the Company’s therapeutic candidates, both alone and
in combination with each other and/or other agents (e.g.,
botensilimab and/or balstilimab in combination); and any other
statements containing the words "may," "believes," "expects,"
"anticipates," "hopes," "intends," "plans," "forecasts,"
"estimates," "will," "establish," "potential," "superiority," "best
in class," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
ContactAgenus Inc.Nico FrelickInvestor
Relations781-674-4616Nico.frelick@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024